文献速递前列腺癌

恩杂鲁胺对前列腺癌患者报告疲劳的影响:关键临床试验数据

Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-09-13

本研究利用四项安慰剂对照试验(ARCHES、PROSPER、PREVAIL、AFFIRM)的患者报告结局,评估恩杂鲁胺对前列腺癌患者疲劳的影响。基线疲劳率在晚期疾病中更高(PROSPER 58%至AFFIRM 86%),起始恩杂鲁胺或安慰剂后13-17周内疲劳早期增加,随后稳定;除AFFIRM外,恩杂鲁胺组疲劳较安慰剂组略高,但组间差异均<10%。

要点

  • 基线疲劳率随疾病分期升高,非转移性CRPC为58%,多西他赛后mCRPC为86%。
  • 起始恩杂鲁胺或安慰剂后13-17周疲劳早期增加,之后趋于稳定或改善。
  • 恩杂鲁胺联合ADT较安慰剂联合ADT的疲劳恶化比例略高,但组间差异<10%。

核心结论

  • 疲劳水平在mCRPC中较高,在较早疾病状态中较低。
  • 起始恩杂鲁胺或安慰剂后前13-17周疲劳小幅增加,之后稳定或改善。
  • 除AFFIRM外,恩杂鲁胺组疲劳略高于安慰剂组,但组间差异<10%。

研究设计与样本

  • 基于四项关键性安慰剂对照试验(ARCHES、PROSPER、PREVAIL、AFFIRM)的患者报告结局分析。
  • 使用FACT-P量表GP1条目在基线、第13或17周及每12周直至疾病进展评估疲劳。
  • 采用均值评分和混合模型重复测量分析纵向变化。

主要发现

  • 基线疲劳率范围从PROSPER(非转移性CRPC)的58%至AFFIRM(多西他赛后mCRPC)的86%。
  • 无论疾病状态,起始恩杂鲁胺或安慰剂后第13或17周疲劳早期增加,随后稳定。
  • 末次评估时,所有试验中≥55%的患者报告疲劳较基线改善或稳定。
  • 在ARCHES、PROSPER和PREVAIL中,恩杂鲁胺联合ADT较安慰剂联合ADT有更多患者疲劳恶化≥1或≥2个单位,但组间差异<10%。

临床怎么用

  • 临床应关注恩杂鲁胺治疗早期(13-17周)的疲劳管理,帮助患者应对。
  • 晚期或经多线治疗患者基线疲劳负担更高,需加强评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fatigue is a multifactorial symptom commonly reported by patients with prostate cancer as a result of disease and treatment. This study assesses the impact enzalutamide has on patient-reported fatigue ("fatigue") by using patient-reported outcomes from four pivotal, placebo-controlled trials of enzalutamide (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVAIL (NCT01212991), and AFFIRM (NCT00974311)). METHODS: Fatigue was assessed in the individual studies using the Functional Assessment of Cancer Therapy-Prostate item GP1 at baseline, weeks 13 or 17, and every 12 weeks until disease progression. Longitudinal changes were assessed using mean scores and mixed-model repeated measures. RESULTS: The fatigue rates at baseline were higher in patients with later-stage disease (metastatic and/or castration-resistant prostate cancer (CRPC)) and among patients who had already received prior treatment lines; rates ranged between 58% in PROSPER (nonmetastatic CRPC) and 86% in AFFIRM (post-docetaxel metastatic CRPC). Irrespective of disease state, initiation of enzalutamide or placebo resulted in an early increase of fatigue (by weeks 13 or 17), with fatigue levels stabilizing thereafter. At last assessment, ≥55% of patients reported fatigue improvement or stabilization in all trials compared to baseline. More patients reported fatigue worsening by ≥1 or ≥2 units with enzalutamide plus androgen deprivation therapy (ADT) than with placebo plus ADT in ARCHES, PROSPER, and PREVAIL, but the between-group difference was <10% in all trials. CONCLUSIONS: The levels of fatigue were greater in mCRPC and lower in earlier states of disease. In all trials, patients reported a small increase in fatigue for the first 13-17 weeks after starting enzalutamide or placebo, with slightly greater fatigue with enzalutamide in all studies except AFFIRM, but fatigue stabilized or improved thereafter. This suggests a role for clinical management of fatigue to help patients cope early in treatment.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tombal BF, Freedland SJ, Armstrong AJ, et al. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer Prostatic Dis. 2021. PMID: 34518652. doi:10.1038/s41391-021-00447-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。